Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1967 14
1968 13
1969 13
1970 19
1971 20
1972 16
1973 26
1974 28
1975 28
1976 28
1977 36
1978 27
1979 23
1980 35
1981 30
1982 42
1983 40
1984 47
1985 47
1986 53
1987 53
1988 57
1989 63
1990 67
1991 57
1992 75
1993 98
1994 114
1995 108
1996 112
1997 148
1998 182
1999 190
2000 181
2001 189
2002 232
2003 259
2004 246
2005 282
2006 320
2007 339
2008 358
2009 417
2010 446
2011 407
2012 424
2013 363
2014 357
2015 335
2016 283
2017 245
2018 174
2019 95
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

7,268 results
Results by year
Filters applied: . Clear all
Page 1
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X, et al. Cancer Treat Rev 2018 - Review. PMID 29870916
In addition, proof-of-principle studies of immunotherapy combined with PARPi in breast cancer have obtained promising results, indicating the potential benefit of the combination therapy in patients with breast cancer. ...In this review, we summarized the utility of combining platinum-PARPi in BRCA mutated breast cancer or TNBC compared with platinum monotherapy and provided promising prospects of PARPi as maintenance therapy in breast cancer, as well as providing a strong rationale for testing immunotherapy combined with PARPi in breast cancer to expand the clinical utility of PARPi....
In addition, proof-of-principle studies of immunotherapy combined with PARPi in breast cancer have obtained promising results, indica …
Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
Yang X, et al. Clin Transl Oncol 2018. PMID 29340974
Although similar degree of enzyme activity inhibition was achieved in both breast cancer and normal breast cells, 6PGD inhibition by siRNA-mediated knockdown or pharmacological inhibitor physcion is more effective in inhibiting growth and survival in breast cancer than normal breast cells. Moreover, inhibiting 6PGD significantly sensitizes breast cancer response to chemotherapeutic agents in in vitro cell culture system and in vivo xenograft breast cancer model. ...
Although similar degree of enzyme activity inhibition was achieved in both breast cancer and normal breast cells, 6PGD inhibit …
High expression of carbonic anhydrase 12 (CA12) is associated with good prognosis in breast cancer.
Li Y, et al. Neoplasma 2019. PMID 30784287
A total of 262 breast cancer specimens and 75 normal breast tissue specimens were recruited in this study. The expression of CA12 was detected by immunohistochemistry (IHC), and its correlation with the clinicopathological characteristics of breast cancer patients and their prognosis were further analyzed through standard statistical algorithms. The result of immunohistochemical staining showed that CA12 was detected in both normal breast tissue and breast cancer tissue. ...
A total of 262 breast cancer specimens and 75 normal breast tissue specimens were recruited in this study. The expression of C …
Dynamic Function of DPMS Is Essential for Angiogenesis and Cancer Progression
Zhang Z, et al. Adv Exp Med Biol 2018. PMID 30637701
Because of the dynamic nature, DPMS actively participates in cellular proliferation enhancing angiogenesis and breast tumor progression. ...We, therefore, conclude that DPMS could become a novel target for developing glycotherapy treating breast tumor in the clinic....
Because of the dynamic nature, DPMS actively participates in cellular proliferation enhancing angiogenesis and breast tumor progressi …
Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer.
Cui Z, et al. Med Sci Monit 2018. PMID 29680858 Free PMC article.
Results of histone modification studies prompted us to explore the therapeutic and prognostic significance of histone deacetylase 3 (HDAC3) expression in patients with breast cancer. ...HDAC3 may be an appropriate prognostic indicator in patients with invasive ductal breast cancer....
Results of histone modification studies prompted us to explore the therapeutic and prognostic significance of histone deacetylase 3 (HDAC3) …
Arginine methyltransferases as novel therapeutic targets for breast cancer.
Morettin A, et al. Mutagenesis 2015 - Review. PMID 25688111
In breast cancer, the expression levels and enzymatic activity of a number of PRMTs is dysregulated; significantly altering the regulation of many cellular pathways that are implicated in breast cancer development and progression. Here, we review the current knowledge on PRMTs in breast cancer and provide a rationale for how PRMTs may provide novel therapeutic targets for the treatment of breast cancer....
In breast cancer, the expression levels and enzymatic activity of a number of PRMTs is dysregulated; significantly altering the regul …
The role of deubiquitinases in breast cancer.
Xiao Z, et al. Cancer Metastasis Rev 2016 - Review. PMID 27844253 Free PMC article.
In breast cancer, growing numbers of DUBs are found to be aberrantly expressed. Depending on their substrates, specific DUBs can either promote or suppress mammary tumors. In this article, we review the role and mechanisms of action of DUBs in breast cancer and discuss the potential of targeting DUBs for cancer treatment....
In breast cancer, growing numbers of DUBs are found to be aberrantly expressed. Depending on their substrates, specific DUBs can eith …
A nanobiosensor for the detection of arginase activity
Malalasekera AP, et al. Nanomedicine 2017. PMID 27558349
Arginase activity was determined in a syngeneic mouse model for aggressive breast cancer (4T1 tumors in BALB/c mice). It was found that the arginase activity is systemically enhanced, but especially pronounced in the active tumor regions....
Arginase activity was determined in a syngeneic mouse model for aggressive breast cancer (4T1 tumors in BALB/c mice). It was found th …
7,268 results
Jump to page
Feedback